Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2012 Jan 25.

Published in final edited form as: Ann Behav Med. 2011 Jun;41(3):284–299. doi: 10.1007/s12160-010-9258-5

Table 3. Percentage screened at 6- and 12-month follow-up by study group for intent-to-treat and per protocol analyses.

Study group	Intent-to-treat(n=1,224)					Per protocol (n=1,046)

	n	6-month follow-up	n	12-month follow-up	n	6-month follow-up	n	12-month follow-up
Any CRCS^a
Survey only	413	30.0	413	34.1	359	33.7	359	37.9
Generic web site	398	31.2	398	35.7	341	33.1	341	37.2
Tailored	413	27.6	413	32.9	346	30.6	346	35.6
COL
Survey only	413	13.8	413	17.4	359	15.6	359	19.2
Generic web site	398	16.6	398	20.9	341	18.2	341	22.0
Tailored	413	15.3	413	19.6	346	16.8	346	21.1
FOBT
Survey only	413	13.8	326	14.0	359	15.6	275	15.9
Generic web site	398	12.6	298	12.8	341	12.6	250	12.9
Tailored	413	10.4	318	11.1	346	11.6	259	11.9
OTHER
Survey only	413	2.4	276	2.7	359	2.5	227	2.8
Generic web site	398	2.0	261	2.0	341	2.4	219	2.4
Tailored	413	1.9	281	2.2	346	2.3	227	2.6

CRCS colorectal cancer screening, COL colonoscopy, FOBT fecal occult blood test, OTHER sigmoidoscopy and/or barium enema

^a

Any CRCS = fecal occult blood test, colonoscopy, sigmoidoscopy, and/or barium enema within 6 or 12 months of physician visit date